Interaction Guide · Research summary

Can I take Radix Et Rhizoma Valerianae with Ziprasidone?

Review Radix Et Rhizoma Valerianae with Ziprasidone: possible adverse effects, preparation details, evidence limits, and sources.

Prepared by Dr. Edward M.Kim, PharmD · Clinical Director, SupplementSafety editorial team

Research summary published · Prepared · Editorial update

The short answer

Confirm the species in this valerian-root product before using it with ziprasidone. Its inventory name does not establish which evidence applies.

What this answer covers

Radix et Rhizoma Valerianae: exact species and preparation unresolved; V. officinalis findings apply only after identity confirmation.

Supplement or preparation
Radix et Rhizoma Valerianae
Medication ingredient
ziprasidone

Confirm the root identity

Ask the pharmacist to verify the Latin species, root or rhizome, extract and other ingredients. A generic valerian-root name is insufficient to establish Valeriana officinalis.

A metabolic study is not a sedation trial

A valerian study using alprazolam as an enzyme probe did not establish a large metabolic interaction. It cannot determine alertness effects with ziprasidone or show that every valerian extract behaves alike.

Identify the complete product

Bring the amount, preparation and other ingredients to the pharmacist. These sources do not provide a universal safe dose or a protective gap between the supplement and medicine.

Watch for impaired alertness

Ziprasidone can affect alertness and coordination. Avoid driving if affected and contact the prescriber if added sleepiness, confusion or unsteadiness appears after a new product. Severe confusion, fainting or inability to wake needs urgent assessment.

Evidence and practical considerations

Side effects & toxicity

Exact unidentified-root interaction remains insufficiently established; product confirmation and conditional alertness review are appropriate.

Exact scope
Radix et Rhizoma Valerianae: exact species and preparation unresolved; V. officinalis findings apply only after identity confirmation. with Exact ziprasidone hydrochloride oral capsules or mesylate intramuscular injection, distinguished by route. Exact RxNorm IN115698; hydrochloride oral capsule and mesylate intramuscular formulation distinct. Oral food and antacid findings do not apply to injection absorption.
Medication form and route
oral; intramuscular
Timing or duration
Source-specific single-dose, repeated-dose and observational exposures distinguished.

What remains uncertain

  • No exact-pair co-use trial identified; standalone or other-medicine findings and product differences prevent a uniform risk estimate.

Factors that may matter: preparation and plant part; clinical indication; dose; other medicines; baseline alertness.

Research conclusion: insufficient evidence · Evidence assessment: low

Read the supporting source summaries

Source 1: current product label

dailymed.nlm.nih.gov · Source check Sep 10, 2026

Population: People prescribed ziprasidone.

Somnolence, QT and electrolyte precautions; low potassium or magnesium requires assessment/correction before proceeding; oral capsules taken with food.

How this applies: Exact RxNorm IN115698; hydrochloride oral capsule and mesylate intramuscular formulation distinct. Oral food and antacid findings do not apply to injection absorption.

No supplement-specific event rate, universal timing rule or untested route/preparation equivalence.

Source 2: official guidance

nccih.nih.gov · Source check Sep 10, 2026

Population: People considering the specified supplement.

Possible but unproven sleep-inducing effect; advises against use with alcohol or sedatives. Mental dullness can occur; long-term safety is uncertain.

How this applies: Preparation-specific evidence; exact ziprasidone co-use is not inferred from another medicine or route.

No ziprasidone interaction trial. Chronic use can be followed by withdrawal symptoms when stopped abruptly.

Source 3: original human study

pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026

Population: Twelve healthy volunteers.

Alprazolam peak concentration increased modestly, but AUC and elimination half-life did not change significantly.

How this applies: Preparation-specific evidence; exact ziprasidone co-use is not inferred from another medicine or route.

PK study is not a clinical sedation safety trial. Exact extract/species cannot resolve an unidentified valerian-root inventory item.

Research assessment: · Open full citations ↗

Review and change history

Publication status
Published research summary
Clinical review
Not yet recorded
DateUpdate
Research summary published
Article prepared
Current exact available claims adjudicated using original captures and explicit identity and comparator limits.

Article revision: 2c2a93fc5666fc71

This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.

Full citations require verification. Reading this answer and the source summaries does not.

Taking other supplements or medications?

Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.

Open the interaction checker

Information, not medical advice. Do not change prescribed treatment based on this guide.